{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:00:18Z","timestamp":1791543618624,"version":"4.3.4"},"reference-count":297,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.pnpbp.2015.11.003","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T12:53:34Z","timestamp":1447332814000},"page":"148-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine"],"prefix":"10.1016","volume":"70","author":[{"given":"Michael","family":"Soyka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Mutschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2015.11.003_bb0005","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2174\/138161210791516440","article-title":"Safety and efficacy of baclofen in the treatment of alcohol-dependent patients","volume":"16","author":"Addolorato","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0010","first-page":"67","article-title":"Ability of baclofen in reducing alcohol craving and intake: II\u2013preliminary clinical evidence","volume":"24","author":"Addolorato","year":"2000","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.alcohol.2009.09.031","article-title":"Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives","volume":"43","author":"Addolorato","year":"2009","journal-title":"Alcohol"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0035","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11060","article-title":"Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation","volume":"11","author":"Adi","year":"2007","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0040","first-page":"213","article-title":"Treating smoking dependence in depressed alcoholics","volume":"29","author":"Ait-Daoud","year":"2006","journal-title":"Alcohol Res. Health"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0045","article-title":"Creating a new problem: the use of baclofen in the management of alcohol use disorder","author":"Akosile","year":"2015","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0055","series-title":"The End of My Addiction","author":"Ameisen","year":"2008"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2009.04.015","article-title":"Modafinil for the treatment of cocaine dependence","volume":"104","author":"Anderson","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0065","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","article-title":"Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures","volume":"94","author":"Angehagen","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","article-title":"A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence","volume":"28","author":"Anton","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0075","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"Anton","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0090","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/j.1530-0277.2012.01807.x","article-title":"Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes","volume":"36","author":"Anton","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0095","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"2000"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0100","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"2013"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0105","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.21098","article-title":"Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation","volume":"21","author":"Ardouin","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pbb.2012.08.019","article-title":"Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol","volume":"103","author":"Ashenhurst","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jad.2008.05.008","article-title":"The impact of one HF-rTMS session on mood and salivary cortisol in treatment resistant unipolar melancholic depressed patients","volume":"113","author":"Baeken","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugalcdep.2006.08.016","article-title":"Disulfiram effects on responses to intravenous cocaine administration","volume":"87","author":"Baker","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.parkreldis.2006.07.011","article-title":"Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease","volume":"13","author":"Bandini","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/09540261.2011.618827","article-title":"Repetitive transcranial magnetic stimulation and drug addiction","volume":"23","author":"Barr","year":"2011","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0135","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00115-013-3879-4","article-title":"Deep brain stimulation for addiction, anorexia and compulsion. Rationale, clinical results and ethical implications","volume":"85","author":"Bartsch","year":"2014","journal-title":"Nervenarzt"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0145","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1111\/acer.12496","article-title":"Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial","volume":"38","author":"Batki","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0150","first-page":"555","article-title":"Treatment of tobacco dependence","volume":"108","author":"Batra","year":"2011","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0160","doi-asserted-by":"crossref","first-page":"815215","DOI":"10.1155\/2014\/815215","article-title":"rTMS in the treatment of drug addiction: an update about human studies","volume":"2014","author":"Bellamoli","year":"2014","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2003.07.007","article-title":"Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence","volume":"55","author":"Bencherif","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0170","series-title":"Treating Alcohol and Drug Abuse \u2014 An Evidence Based Review","author":"Berglund","year":"2003"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1345\/aph.10093","article-title":"Topiramate titration and tolerability","volume":"35","author":"Biton","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0180","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/ADM.0000000000000115","article-title":"Prevalent intravenous abuse of methylphenidate among treatment-seeking patients with substance abuse disorders: a descriptive population-based study","volume":"9","author":"Bjarnadottir","year":"2015","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0185","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0190","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction","volume":"95","author":"Bond","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2007-979203","article-title":"Treatment of alcohol withdrawal syndrome with gabapentin","volume":"32","author":"Bonnet","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0278-5846(01)00234-2","article-title":"Treatment of alcohol withdrawal with gabapentin","volume":"26","author":"Bozikas","year":"2002","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0205","doi-asserted-by":"crossref","first-page":"g2017","DOI":"10.1136\/bmj.g2017","article-title":"Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency","volume":"348","author":"Braillon","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S1461145702002791","article-title":"Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis","volume":"5","author":"Burt","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0215","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1192\/bjp.bp.112.111583","article-title":"Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction","volume":"203","author":"Byford","year":"2013","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1369-1600.2012.00456.x","article-title":"Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations","volume":"19","author":"Calipari","year":"2014","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.pnpbp.2015.11.003_bb9000","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.drugalcdep.2006.06.002","article-title":"One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving","volume":"86","author":"Camprodon","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archpsyc.61.3.264","article-title":"Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial","volume":"61","author":"Carroll","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0230","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1360-0443.2000.95913355.x","article-title":"One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment","volume":"95","author":"Carroll","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0235","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1360-0443.1998.9357137.x","article-title":"Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram","volume":"93","author":"Carroll","year":"1998","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.pnpbp.2015.11.003_bb9005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1139\/cjpp-2014-0188","article-title":"Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study","volume":"93","author":"Ceccanti","year":"2015","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0240","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis","volume":"17","author":"Chamorro","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0245","first-page":"519","article-title":"Deep brain stimulation in neurological and psychiatric disorders","volume":"112","author":"Coenen","year":"2015","journal-title":"DtschArztebl Int."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2009.11.001","article-title":"The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review","volume":"20","author":"Crunelle","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euroneuro.2010.11.001","article-title":"Dose-dependent and sustained effects of varenicline on dopamine D2\/3 receptor availability in rats","volume":"21","author":"Crunelle","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0260","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.npp.1300600","article-title":"A double-blind, placebo-controlled trial of modafinil for cocaine dependence","volume":"30","author":"Dackis","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0265","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jsat.2011.12.014","article-title":"A double-blind, placebo-controlled trial of modafinil for cocaine dependence","volume":"43","author":"Dackis","year":"2012","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0270","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/01.alc.0000187599.17786.4a","article-title":"Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism","volume":"29","author":"Dai","year":"2005","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0275","article-title":"Which medications are suitable for agonist drug maintenance?","author":"Darke","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0280","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/070674370805300902","article-title":"Repetitive transcranial magnetic stimulation for major depressive disorder: a review","volume":"53","author":"Daskalakis","year":"2008","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0285","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1530-0277.2012.01846.x","article-title":"Recent advances in the discovery and preclinical testing of novel compounds for the prevention and\/or treatment of alcohol use disorders","volume":"37","author":"Davies","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0290","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0295","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/add.12551","article-title":"The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0300","article-title":"Causes of death in a cohort treated for opioid dependence between 1985 and 2005","author":"Degenhardt","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0305","doi-asserted-by":"crossref","first-page":"e0135524","DOI":"10.1371\/journal.pone.0135524","article-title":"Effects of deep brain stimulation on the lived experience of obsessive\u2013compulsive disorder patients: in-depth interviews with 18 patients","volume":"10","author":"de Haan","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pnpbp.2015.11.003_bb9010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neulet.2011.03.074","article-title":"Transient alcohol craving suppression by rTMS of dorsal anterior cingulate: an fMRI and LORETA EEG study","volume":"496","author":"De Ridder","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0310","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/j.1552-4604.1987.tb02191.x","article-title":"Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist","volume":"27","author":"Dixon","year":"1987","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0315","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/add.12875","article-title":"The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis","volume":"110","author":"Donoghue","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0320","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.npp.1300101","article-title":"A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene","volume":"28","author":"Drobes","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0325","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","article-title":"Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers","volume":"28","author":"Drobes","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0330","article-title":"Reductions in cortico-striatal hyperconnectivity accompany successful treatment of obsessive\u2013compulsive disorder with dorsomedial prefrontal rTMS","author":"Dunlop","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0335","series-title":"The Brain\u2013Behavioral Connection in Substance Use Disorders and Effects Associated with Injectable Opioid Prescription","author":"Dursteler","year":"2015"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/SAR.S50807","article-title":"Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence","volume":"6","author":"Dursteler","year":"2015","journal-title":"Subst. Abus. Rehabil."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0350","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/138161211796150765","article-title":"Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review","volume":"17","author":"Edwards","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0355","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1360-0443.2004.00611.x","article-title":"Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram's psychological effects","volume":"99","author":"Ehrenreich","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0360","series-title":"Selincro (Nalmefene): Summary of Product Characteristics","author":"EMA","year":"2014"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0365","series-title":"European Drug Report 2014: Trends and Developments","author":"EMCDDA","year":"2014"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0370","series-title":"Mortality Among Drug Users in Europe: New and Old Challenges for Public Health","author":"EMCDDA","year":"2015"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0375","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0022-3565(25)24051-4","article-title":"Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes","volume":"271","author":"Emmerson","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0380","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/jnnp-2013-306103.22","article-title":"A review of stress and endogenous opioid interaction in alcohol addiction","volume":"84","author":"Emsley","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0385","first-page":"CD005041","article-title":"Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults","volume":"9","author":"Epstein","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0390","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1177\/1060028014545806","article-title":"Varenicline in the treatment of alcohol use disorders","volume":"48","author":"Erwin","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0395","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuropharm.2013.07.007","article-title":"S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study","volume":"75","author":"Faiman","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0400","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.neubiorev.2009.11.006","article-title":"Brain stimulation in the study and treatment of addiction","volume":"34","author":"Feil","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0405","first-page":"CD003410","article-title":"Heroin maintenance for chronic heroin-dependent individuals","author":"Ferri","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0410","first-page":"CD009879","article-title":"Slow-release oral morphine as maintenance therapy for opioid dependence","volume":"6","author":"Ferri","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0415","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.clinph.2006.06.712","article-title":"A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition","volume":"117","author":"Fitzgerald","year":"2006","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0420","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.clinph.2009.06.019","article-title":"GABA and cortical inhibition in motor and non-motor regions using combined TMS-EEG: a time analysis","volume":"120","author":"Fitzgerald","year":"2009","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0425","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.conb.2013.05.005","article-title":"Pharmacotherapy for alcohol dependence: status of current treatments","volume":"23","author":"Franck","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0430","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0435","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/acer.12148","article-title":"Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone","volume":"37","author":"Froehlich","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0440","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.psychres.2013.11.008","article-title":"Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions","volume":"215","author":"Gahr","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0445","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0450","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bcp.12031","article-title":"Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?","volume":"77","author":"Garcia-Portilla","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0455","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1530-0277.2007.00339.x","article-title":"Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study","volume":"31","author":"Gelernter","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1568026043451573","article-title":"Endogenous opioids and addiction to alcohol and other drugs of abuse","volume":"4","author":"Gianoulakis","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2015.152","article-title":"The novel mu-opioid receptor antagonist GSK1521498 decreases both alcohol seeking and drinking: evidence from a new preclinical model of alcohol seeking","author":"Giuliano","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0470","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/nyas.12479","article-title":"Transcranial magnetic stimulation in the treatment of substance addiction","volume":"1327","author":"Gorelick","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb9015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fnhum.2014.00661","article-title":"Modulation of risky choices in recently abstinent dependent cocaine users: a transcranial direct-current stimulation study","volume":"8","author":"Gorini","year":"2014","journal-title":"Front Hum. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0475","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/add.12899","article-title":"Global statistics on addictive behaviours: 2014 status report","volume":"110","author":"Gowing","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0480","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fpsyt.2015.00114","article-title":"Severity of depression predicts remission rates using transcranial magnetic stimulation","volume":"6","author":"Grammer","year":"2015","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0485","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0490","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archpsyc.61.4.361","article-title":"Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"61","author":"Grant","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0495","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.phrs.2006.11.005","article-title":"Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study","volume":"55","author":"Grassi","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0500","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.2741\/3029","article-title":"The evolution of deep brain stimulation for neuropsychiatric disorders","volume":"13","author":"Greenberg","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0505","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/dar.12062","article-title":"Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics","volume":"32","author":"Groshkova","year":"2013","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0510","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0515","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1530-0277.2010.01369.x","article-title":"Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study","volume":"35","author":"Gueorguieva","year":"2011","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0520","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40263-015-0244-0","article-title":"Topiramate in alcohol use disorders: review and update","volume":"29","author":"Guglielmo","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0525","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jsat.2014.05.012","article-title":"Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence","volume":"47","author":"Hammig","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0530","series-title":"Trend of Substance Use Among Israel Youth: Findings from the Israel-HBSC Survey 1994\u20132011","author":"Harel-Fisch","year":"2013"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0535","article-title":"Cognitive effects of high-frequency rTMS in schizophrenia patients with predominant negative symptoms: results from a multicenter randomized sham-controlled trial","author":"Hasan","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0540","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pharmthera.2006.02.001","article-title":"Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms","volume":"111","author":"Heilig","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0545","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.tins.2007.06.006","article-title":"A key role for corticotropin-releasing factor in alcohol dependence","volume":"30","author":"Heilig","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0550","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.62.1.57","article-title":"Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil","volume":"62","author":"Heinz","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136182","article-title":"The impact of accelerated right prefrontal high-frequency repetitive transcranial magnetic stimulation (rTMS) on cue-reactivity: an fMRI study on craving in recently detoxified alcohol-dependent patients","volume":"10","author":"Herremans","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0560","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4088\/JCP.13m08940","article-title":"Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study)","volume":"76","author":"Higuchi","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.pnpbp.2015.11.003_bb8005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/15622975.2011.598383","article-title":"Repetitive transcranial magnetic stimulation (rTMS) for treatment of alcohol dependence","volume":"12","author":"H\u00f6ppner","year":"2011","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0565","article-title":"Glutamatergic and neurometabolic alterations in chronic cocaine users measured with H-magnetic resonance spectroscopy","author":"Hulka","year":"2014","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0570","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamapsychiatry.2013.1273","article-title":"Stimulant medication and substance use outcomes: a meta-analysis","volume":"70","author":"Humphreys","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0575","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/acer.12823","article-title":"Anticraving effect of baclofen in alcohol-dependent patients","volume":"39","author":"Imbert","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0580","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1747-597X-9-43","article-title":"Harms of prescription opioid use in the United States","volume":"9","author":"Imtiaz","year":"2014","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0585","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/sj.npp.1300790","article-title":"Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing","volume":"30","author":"Ingman","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0590","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/00952990.2013.796961","article-title":"Naltrexone (50mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials","volume":"39","author":"Jarosz","year":"2013","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0595","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00023210-200519100-00005","article-title":"Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function","volume":"19","author":"Johnson","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0600","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","article-title":"Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings","volume":"75","author":"Johnson","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0605","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2174\/138161210791516404","article-title":"Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients","volume":"16","author":"Johnson","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0610","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0615","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0620","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0625","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0630","first-page":"2174","article-title":"The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats","volume":"22","author":"June","year":"1998","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0635","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/mp.2011.46","article-title":"New medications for drug addiction hiding in glutamatergic neuroplasticity","volume":"16","author":"Kalivas","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0640","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0645","article-title":"Dependence on supratherapeutic doses of modafinil: a case report","volume":"14","author":"Kate","year":"2012","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0650","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/09595230412331324518","article-title":"Injecting and non-injecting cocaine use in Sydney, Australia: physical and psychological morbidity","volume":"23","author":"Kaye","year":"2004","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0655","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","article-title":"Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence","volume":"34","author":"Keating","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0660","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/NRL.0b013e3181492c48","article-title":"Deep brain stimulation","volume":"13","author":"Kern","year":"2007","journal-title":"Neurologist"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0665","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/archgenpsychiatry.2011.160","article-title":"Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement","volume":"69","author":"Kessler","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0670","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0675","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1176\/ajp.140.6.784","article-title":"An extreme case of cocaine dependence and marked improvement with methylphenidate treatment","volume":"140","author":"Khantzian","year":"1983","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0680","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00213-008-1330-5","article-title":"A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients","volume":"201","author":"Kim","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0685","first-page":"5","article-title":"Treatment of patients with substance use disorders","volume":"164","author":"Kleber","year":"2007","journal-title":"Am. Psychiatr. Assoc. Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0690","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.pbb.2009.01.017","article-title":"Deep brain stimulation of the nucleus accumbens reduces ethanol consumption in rats","volume":"92","author":"Knapp","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0695","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1523\/JNEUROSCI.0804-06.2006","article-title":"Disruption of right prefrontal cortex by low-frequency repetitive transcranial magnetic stimulation induces risk-taking behavior","volume":"26","author":"Knoch","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0700","doi-asserted-by":"crossref","first-page":"467","DOI":"10.15288\/jsad.2014.75.467","article-title":"Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders","volume":"75","author":"Knudsen","year":"2014","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0705","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0091-3057(01)00464-6","article-title":"Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review","volume":"68","author":"Kollins","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0710","series-title":"Drugs, Addiction, and the Brain","author":"Koob","year":"2014"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0715","first-page":"263","article-title":"Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology","volume":"16","author":"Koob","year":"2003","journal-title":"Recent Dev. Alcohol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0720","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0725","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.biopsych.2012.07.011","article-title":"Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase","volume":"73","author":"Kosten","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0730","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1017\/S1461145714000510","article-title":"GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink","volume":"17","author":"Kranzler","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0735","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism","volume":"171","author":"Kranzler","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0740","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1369-1600.2012.00471.x","article-title":"Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment","volume":"18","author":"Kranzler","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2015.03.048","article-title":"Cortico-striatal circuits: novel therapeutic targets for substance use disorders","author":"Kravitz","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0750","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0976-500X.149149","article-title":"A rare case modafinil dependence","volume":"6","author":"Krishnan","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0755","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0760","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1055\/s-0031-1281733","article-title":"Deep brain stimulation in schizophrenia","volume":"79","author":"Kuhn","year":"2011","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0765","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1369-1600.2011.00337.x","article-title":"Successful deep brain stimulation of the nucleus accumbens in severe alcohol dependence is associated with changed performance monitoring","volume":"16","author":"Kuhn","year":"2011","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0770","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000228930","article-title":"Observations on unaided smoking cessation after deep brain stimulation of the nucleus accumbens","volume":"15","author":"Kuhn","year":"2009","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0775","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/jnnp.2006.113092","article-title":"Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: valuable therapeutic implications?","volume":"78","author":"Kuhn","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0780","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0785","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.drugalcdep.2006.07.004","article-title":"Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo","volume":"87","author":"Levin","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0790","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.clinph.2007.09.061","article-title":"A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation","volume":"118","author":"Levkovitz","year":"2007","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0795","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.drugalcdep.2013.06.032","article-title":"Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial","volume":"133","author":"Likhitsathian","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0800","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0805","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0810","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/acer.12357","article-title":"Alcohol medications development: advantages and caveats of government\/academia collaborating with the pharmaceutical industry","volume":"38","author":"Litten","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0815","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"J. Addict. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2015.11.003_bb0820","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1521-0391.2003.tb00492.x","article-title":"Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence","volume":"12","author":"Littleton","year":"2003","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0825","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1369-1600.2007.00088.x","article-title":"Chronic deep brain stimulation in the rat nucleus accumbens and its effect on morphine reinforcement","volume":"13","author":"Liu","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0830","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","article-title":"Naltrexone depot formulations for opioid and alcohol dependence: a systematic review","volume":"17","author":"Lobmaier","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0835","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/mp.2011.114","article-title":"Deep brain stimulation in addiction: a review of potential brain targets","volume":"17","author":"Luigjes","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0840","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/add.12773","article-title":"Is deep brain stimulation a treatment option for addiction?","volume":"110","author":"Luigjes","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0845","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1360-0443.2009.02653.x","article-title":"A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification","volume":"104","author":"Madlung-Kratzer","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0850","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.4155\/bio.14.207","article-title":"Retrospective monitoring of long-term recreational and dependent cocaine use in toenail clippings\/scrapings as an alternative to hair","volume":"6","author":"Madry","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0855","doi-asserted-by":"crossref","first-page":"e0129805","DOI":"10.1371\/journal.pone.0129805","article-title":"Pharmacological cognitive enhancement in healthy individuals: a compensation for cognitive deficits or a question of personality?","volume":"10","author":"Maier","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0860","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0865","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1517\/14656560903213405","article-title":"The clinical efficacy and abuse potential of combination buprenorphine\u2013naloxone in the treatment of opioid dependence","volume":"10","author":"Mammen","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0870","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0875","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/adb.12012","article-title":"Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study","volume":"18","author":"Mann","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0880","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1227\/01.NEU.0000360570.40339.64","article-title":"Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report","volume":"66","author":"Mantione","year":"2010","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0885","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1176\/appi.ajp.162.10.1983","article-title":"Psychosis associated with modafinil and shift work","volume":"162","author":"Mariani","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0890","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/01.alc.0000183008.62955.2e","article-title":"A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration","volume":"29","author":"Marinelli","year":"2005","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0895","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1530-0277.2006.00112.x","article-title":"A microdialysis profile of dynorphin A(1\u20138) release in the rat nucleus accumbens following alcohol administration","volume":"30","author":"Marinelli","year":"2006","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0900","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.neuroscience.2004.05.047","article-title":"An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol","volume":"127","author":"Marinelli","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0905","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.279.22.1795","article-title":"Ambient temperature and mortality from unintentional cocaine overdose","volume":"279","author":"Marzuk","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0910","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/ajp.149.3.371","article-title":"Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period","volume":"149","author":"Marzuk","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0915","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0920","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0925","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0930","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0935","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0940","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0376-8716(98)00050-7","article-title":"Disulfiram effects on acute cocaine administration","volume":"52","author":"McCance-Katz","year":"1998","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0945","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1176\/appi.neuropsych.13010013","article-title":"Comparison of anticraving efficacy of right and left repetitive transcranial magnetic stimulation in alcohol dependence: a randomized double-blind study","volume":"27","author":"Mishra","year":"2015","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0950","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0955","doi-asserted-by":"crossref","DOI":"10.1093\/alcalc\/agu062","article-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","author":"Morley","year":"2014","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0960","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1517\/14656566.2014.876008","article-title":"Current pharmacological treatment approaches for alcohol dependence","volume":"15","author":"Muller","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0965","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","article-title":"High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial","volume":"25","author":"Muller","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0970","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-0029-1233489","article-title":"Successful treatment of chronic resistant alcoholism by deep brain stimulation of nucleus accumbens: first experience with three cases","volume":"42","author":"Muller","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0975","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1024\/1661-8157\/a001178","article-title":"Mechanism of action of disulfiram and treatment optimization in prevention of recurrent alcoholism","volume":"102","author":"Mutschler","year":"2013","journal-title":"Praxis"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0980","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mehy.2009.07.007","article-title":"Disulfiram, an old drug with new potential in the treatment of pathological gambling?","volume":"74","author":"Mutschler","year":"2010","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0985","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JCP.0b013e3181934451","article-title":"Pronounced paranoia as a result of cocaine-disulfiram interaction: case report and mode of action","volume":"29","author":"Mutschler","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0990","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/WNF.0b013e3182216fd5","article-title":"Experienced acetaldehyde reaction does not improve treatment response in outpatients treated with supervised disulfiram","volume":"34","author":"Mutschler","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb0995","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1176\/ajp.155.11.1626j","article-title":"Gabapentin treatment of alcohol withdrawal","volume":"155","author":"Myrick","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(00)00099-1","article-title":"Regulations of opioid dependence by opioid receptor types","volume":"89","author":"Narita","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1005","series-title":"Opioid Treatment Program: Clinical Guidelines for Methadone and Buprenorphine Treatment","author":"New South Wales Department of Health","year":"2006"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40263-013-0096-4","article-title":"Targeted opioid receptor antagonists in the treatment of alcohol use disorders","volume":"27","author":"Niciu","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1521-0391.2013.12037.x","article-title":"Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction?","volume":"22","author":"Nocente","year":"2013","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.drugpo.2009.02.009","article-title":"Low-threshold methadone treatment, heroin price, police activity and incidence of heroin use: the Zurich experience","volume":"20","author":"Nordt","year":"2009","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1025","series-title":"Neurobiology of Alcohol Dependence","author":"Noronha","year":"2014"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1030","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0269881115582151","article-title":"Modafinil in the treatment of crack-cocaine dependence in the Netherlands: results of an open-label randomised controlled feasibility trial","volume":"29","author":"Nuijten","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0269881113504017","article-title":"The role of the opioid system in alcohol dependence","volume":"28","author":"Nutt","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1040","series-title":"Addiction","author":"Nutt","year":"2013"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1037\/h0058775","article-title":"Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain","volume":"47","author":"Olds","year":"1954","journal-title":"J. Comp. Physiol. Psychol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1050","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.drugalcdep.2010.07.022","article-title":"Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients","volume":"113","author":"Oliveto","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1055","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.4088\/JCP.13m08934","article-title":"Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety","volume":"76","author":"O'Malley","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1530-0277.2008.00846.x","article-title":"OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach","volume":"33","author":"Oroszi","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1065","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1070","first-page":"CD008544","article-title":"Anticonvulsants for alcohol dependence","volume":"2","author":"Pani","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1075","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinte.1991.00400040119027","article-title":"Intravenous methylphenidate abuse. Prototype for prescription drug abuse","volume":"151","author":"Parran","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00115-009-2916-9","article-title":"Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?","volume":"81","author":"Paslakis","year":"2010","journal-title":"Nervenarzt"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2009.09.013","article-title":"15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel","volume":"107","author":"Peles","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jsat.2014.12.010","article-title":"Differences in methylphenidate abuse rates among methadone maintenance treatment patients in two clinics","volume":"54","author":"Peles","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1360-0443.2000.9522198.x","article-title":"Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts","volume":"95","author":"Petrakis","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.addbeh.2007.11.011","article-title":"A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence","volume":"33","author":"Pettinati","year":"2008","journal-title":"Addict. Behav."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/alcalc\/agh240","article-title":"Currently active and remitted alcohol dependence in a nationwide adult general population\u2014results from the Finnish Health 2000 study","volume":"41","author":"Pirkola","year":"2006","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1110","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.drugalcdep.2013.06.019","article-title":"Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence","volume":"133","author":"Plebani","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.pnpbp.2015.11.003_bb8000","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10550490802139283","article-title":"Daily sessions of transcranial magnetic stimulation to the left prefrontal cortex gradually reduce cocaine craving","volume":"17","author":"Politi","year":"2008","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","article-title":"Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1year follow-up","volume":"52","author":"Ponizovsky","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1369-1600.2007.00061.x","article-title":"New developments in the pharmacotherapy of cocaine abuse","volume":"12","author":"Preti","year":"2007","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pnpbp.2013.10.019","article-title":"Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients","volume":"49","author":"Prikryl","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.15288\/jsa.1998.59.631","article-title":"Matching alcoholism treatments to client heterogeneity: treatment main effects and matching effects on drinking during treatment","volume":"59","author":"Project MATCH Research Group","year":"1998","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1135","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1871527314666150318114043","article-title":"Repetitive transcranial magnetic stimulation to treat substance use disorders and compulsive behavior","volume":"14","author":"Protasio","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1140","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/acer.12828","article-title":"Prazosin+naltrexone decreases alcohol drinking more effectively than does either drug alone in P rats with a protracted history of extensive voluntary alcohol drinking, dependence, and multiple withdrawals","volume":"39","author":"Rasmussen","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.euroneuro.2005.04.005","article-title":"Alcohol use disorders in EU countries and Norway: an overview of the epidemiology","volume":"15","author":"Rehm","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1150","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1126\/science.2820058","article-title":"Cocaine receptors on dopamine transporters are related to self-administration of cocaine","volume":"237","author":"Ritz","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2003.08.061","article-title":"Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice","volume":"479","author":"Rocha","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1160","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1165","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/JCP.0b013e3182860e84","article-title":"Baclofen for alcohol-dependence: anticraving or partial substitution?","volume":"33","author":"Rolland","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2015.05.008","article-title":"Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation","author":"Rolland","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1175","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1180","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1185","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1190","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.clinph.2009.08.016","article-title":"Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research","volume":"120","author":"Rossi","year":"2009","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1195","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1073\/pnas.0908189107","article-title":"Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation","volume":"107","author":"Rouaud","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1200","first-page":"5","article-title":"A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome","volume":"58","author":"Rustembegovic","year":"2004","journal-title":"Med. Arh."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1205","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/npp.2012.195","article-title":"Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues","volume":"38","author":"Schacht","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drugalcdep.2013.12.007","article-title":"Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment","volume":"136","author":"Schottenfeld","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1215","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/pgs.12.99","article-title":"Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone","volume":"13","author":"Setiawan","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728214.2015.985203","article-title":"Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy","volume":"20","author":"Shorter","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1225","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.euroneuro.2013.05.014","article-title":"Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha1A-adrenoceptor gene variation","volume":"23","author":"Shorter","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1230","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2014.863278","article-title":"Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention","volume":"15","author":"Skala","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1240","first-page":"271","article-title":"Repetitive transcranial magnetic stimulation (rTMS) in the management of alcohol dependence and other substance abuse disorders \u2014 emerging data and clinical relevance","volume":"4","author":"Sousa","year":"2013","journal-title":"Basic Clin. Neurosc."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/SAR.S45585","article-title":"New developments in the management of opioid dependence: focus on sublingual buprenorphine\u2013naloxone","volume":"6","author":"Soyka","year":"2015","journal-title":"Subst. Abuse Rehabil."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0035-1547237","article-title":"Recent developments in pharmacotherapy of alcoholism","volume":"48","author":"Soyka","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1255","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1517\/14728214.2010.500811","article-title":"Emerging drugs to treat alcoholism","volume":"15","author":"Soyka","year":"2010","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/15622975.2011.561872","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence","volume":"12","author":"Soyka","year":"2011","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1265","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e31822cd446","article-title":"Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study","volume":"31","author":"Soyka","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tips.2007.12.005","article-title":"Drugs for relapse prevention of alcoholism: ten years of progress","volume":"29","author":"Spanagel","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1275","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/978-3-642-28720-6_205","article-title":"New pharmacological treatment strategies for relapse prevention","volume":"13","author":"Spanagel","year":"2013","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tins.2014.02.006","article-title":"Stress and alcohol interactions: animal studies and clinical significance","volume":"37","author":"Spanagel","year":"2014","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1285","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1290","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/FPC.0b013e328361c39d","article-title":"ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse","volume":"23","author":"Spellicy","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1295","doi-asserted-by":"crossref","first-page":"g1531","DOI":"10.1136\/bmj.g1531","article-title":"Bad medicine: nalmefene in alcohol misuse","volume":"348","author":"Spence","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1300","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1360-0443.2011.03656.x","article-title":"Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis","volume":"107","author":"Stephen","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1305","series-title":"Neurobiology of Alcohol Dependence","first-page":"429","article-title":"The potential role of glucocorticoids and the HPA axis in alcohol dependence","author":"Stephens","year":"2014"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1310","doi-asserted-by":"crossref","first-page":"RC157","DOI":"10.1523\/JNEUROSCI.21-15-j0003.2001","article-title":"Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus","volume":"21","author":"Strafella","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1315","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","article-title":"Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addictiondagger","volume":"207","author":"Strang","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1320","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(10)60349-2","article-title":"Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial","volume":"375","author":"Strang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1325","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1330","doi-asserted-by":"crossref","DOI":"10.1016\/j.brs.2015.06.010","article-title":"Deep brain stimulation modulates gamma oscillations and theta\u2013gamma coupling in treatment resistant depression","author":"Sun","year":"2015","journal-title":"Brain Stimul."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1335","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2013.03.002","article-title":"Naltrexone and nalmefene: any meaningful difference?","volume":"73","author":"Swift","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1340","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL(R)): a review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1345","first-page":"219","article-title":"Naltrexone extended-release injection: an option for the management of opioid abuse","volume":"2","author":"Taylor","year":"2011","journal-title":"Subst. Abuse Rehabil."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1350","series-title":"2006 World Drug Report","author":"United Nations Office on Drugs and Crime","year":"2006"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1355","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.biopsych.2011.12.013","article-title":"Effective deep brain stimulation in heroin addiction: a case report with complementary intracranial electroencephalogram","volume":"71","author":"Valencia-Alfonso","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1360","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1365","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2013.09.026","article-title":"Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria","volume":"134","author":"van de Glind","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1370","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2012.07.011","article-title":"Deep brain stimulation surgery for alcohol addiction","volume":"80","author":"Voges","year":"2013","journal-title":"World Neurosurg."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1375","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1530-0277.2008.00783.x","article-title":"Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm\u2013possible influence of self-control","volume":"32","author":"Voronin","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1380","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1385","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alcohol.2011.10.006","article-title":"Targeting dynorphin\/kappa opioid receptor systems to treat alcohol abuse and dependence","volume":"46","author":"Walker","year":"2012","journal-title":"Alcohol"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1390","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1369-1600.2010.00226.x","article-title":"Systemic kappa-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats","volume":"16","author":"Walker","year":"2011","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1395","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0028-3908(97)00118-4","article-title":"The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome","volume":"36","author":"Watson","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1400","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/nm0910-969","article-title":"Cocaine sobers up","volume":"16","author":"Weinshenker","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1405","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/sj.npp.1301263","article-title":"There and back again: a tale of norepinephrine and drug addiction","volume":"32","author":"Weinshenker","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1410","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.26.3.375","article-title":"Topiramate for migraine prevention","volume":"26","author":"Wenzel","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2015.11.003_bb1415","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1420","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"WHO","year":"1992"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1425","series-title":"The World Health Report 2004","author":"WHO","year":"2004"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1430","series-title":"Global Status Report on Alcohol and Health","author":"WHO","year":"2011"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1435","series-title":"Expert Committee on Drug Dependence 35th Meeting, Hammamet, Tunisia, 4\u20138 June 2012","article-title":"Gamma-hydroxybutyric acid (GHB). Critical review report","author":"WHO","year":"2012"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1440","first-page":"421","article-title":"Comorbidity of attention-deficit hyperactivity and psychoactive substance use disorders","volume":"45","author":"Wilens","year":"1994","journal-title":"Hospital Community Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1445","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.biopsych.2011.02.012","article-title":"Deep brain stimulation of nucleus accumbens on heroin-seeking behaviors: a case report","volume":"69","author":"Zhou","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"Suppl. 17","key":"10.1016\/j.pnpbp.2015.11.003_bb1450","doi-asserted-by":"crossref","first-page":"79","DOI":"10.15288\/jsads.2014.s17.79","article-title":"Pharmacotherapy of alcohol use disorders: seventy-five years of progress","volume":"75","author":"Zindel","year":"2014","journal-title":"J. Stud. Alcohol Drugs Suppl."},{"key":"10.1016\/j.pnpbp.2015.11.003_bb1455","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.drugalcdep.2012.12.017","article-title":"Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism","volume":"128","author":"Zorrilla","year":"2013","journal-title":"Drug Alcohol Depend."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584615300579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584615300579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:28:22Z","timestamp":1748676502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584615300579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":297,"alternative-id":["S0278584615300579"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2015.11.003","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}